Top therapy spending areas in pharmerging markets 2018

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

This statistic shows the top therapy areas in the "pharmerging" markets as projected for 2018, by spending in billion US dollars. By 2018, expenditure on oncology in these markets is projected to reach between 12 and 14 billion U.S. dollars.

Top therapy areas in pharmerging markets in 2018, by spending (in billion U.S. dollars)*

Characteristic	Minimum estimate	Maximum estimate
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

November 2014

More information

Region

Worldwide

Survey time period

2014

Supplementary notes

* Forecast.
Spending in US$ with variable exchange rates. Growth in US$ with constant exchange rates. Specialty therapies are defined by IMS as products that are often injectable, high-cost, biologic or requiring cold-chain distribution. They are mostly used by specialists, and include treatment for cancer and other serious conditions, and often involve complex patient follow-up and monitoring. Therapy forecasts from IMS Health Therapy Prognosis Global October 2014 adapted by IMS Health Institute for Healthcare Informatics to represent global sales and to include additional therapy classes. Abbreviations: ADHD: Attention-Deficit Hyperactivity Disorder; CNS: Central Nervous System; HIV: Human Immunodeficiency Virus.

Open this statistic in...

Spanish

Citation formats